Sibrotuzumab: Difference between revisions
m (Protected "Sibrotuzumab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
Line 26: | Line 26: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
Line 32: | Line 32: | ||
{{humanizedmonoclonals}} | {{humanizedmonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
[[Category:Cancer treatments]] | [[Category:Cancer treatments]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Latest revision as of 16:02, 20 August 2012
WikiDoc Resources for Sibrotuzumab |
Articles |
---|
Most recent articles on Sibrotuzumab Most cited articles on Sibrotuzumab |
Media |
Powerpoint slides on Sibrotuzumab |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Sibrotuzumab at Clinical Trials.gov Clinical Trials on Sibrotuzumab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Sibrotuzumab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Sibrotuzumab Discussion groups on Sibrotuzumab Patient Handouts on Sibrotuzumab Directions to Hospitals Treating Sibrotuzumab Risk calculators and risk factors for Sibrotuzumab
|
Healthcare Provider Resources |
Causes & Risk Factors for Sibrotuzumab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Overview
Sibrotuzumab is a humanized monoclonal antibody that is used to treat cancer.